Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12/23p40 in a TNBS-induced Crohn's disease model

Digestive Diseases and Sciences

Volumn 56, Issue 8, 2011, Pages 2283-2291

  Radi, Zaher A ^a   Heuvelman, Deborah M ^a   Masferrer, Jaime L ^a   Benson, Ericka L ^a  

^a PFIZER INC   (United States)

Author keywords

Anti IL 12 23p40; FTY720; IBD; Sulfasalazine; TNBS

Indexed keywords

ALCOHOL; FINGOLIMOD; INTERLEUKIN 12 INTERLEUKIN 23P40 ANTIBODY; MONOCLONAL ANTIBODY; SALAZOSULFAPYRIDINE; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON WEIGHT; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DISEASE MODEL; DRUG EFFICACY; DRUG SCREENING; FEMALE; INTESTINE INJURY; INTESTINE PARAMETERS; MOUSE; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DIARRHEA; DISEASE MODELS, ANIMAL; FEMALE; GASTROINTESTINAL AGENTS; INTERLEUKIN-12; INTERLEUKIN-23; MICE; MICE, INBRED BALB C; ORGAN SIZE; PROPYLENE GLYCOLS; SPHINGOSINE; SULFASALAZINE; TRINITROBENZENESULFONIC ACID; WEIGHT LOSS;

EID: 79960935591     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1628-8     Document Type: Article

References (17)

1. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol. 2006;12:4807-4812. (Pubitemid 44323204)
2. Bouma G, Kaushiva A, Strober W. Experimental murine colitis is regulated by two genetic loci, including one on chromosome 11 that regulates IL-12 responses. Gastroenterology. 2002;123:554-565. (Pubitemid 34827199)
3. Thia KT, Loftus EV Jr, Sandborn WJ, et al. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008;103:3167-3182.
4. Elson CO, Beagley KW, Sharmanov AT, et al. Hapten-induced model of murine inflammatory bowel disease: Mucosa immune responses and protection by tolerance. J Immunol. 1996;157:2174-2185. (Pubitemid 126449698)
5. Scheiffele F, Fuss IJ. Induction of TNBS colitis in mice. Curr Protoc Immuno. 2002;Chapter 15:Unit 15.19.
6. Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: Top-down versus step-up. Med Clin North Am. 2010;94:1-18
7. in murine TNBS-induced colitis. Inflamm Bowel Dis. 2006;12:995-999.
8. Takabe K, Paugh SW, Milstien S, et al. "Inside-out" signaling of sphingosine-1-phosphate: Therapeutic targets. Pharmacol Rev. 2008;60:181-195.
9. Halfvarson J, Bodin L, Tysk C, et al. Inflammatory bowel disease in a Swedish twin cohort: A long-term follow-up of concordance and clinical characteristics. Gastroenterology. 2003;124:1767-1773. (Pubitemid 36666773)
10. Vavricka SR, Rogler G. New insights into the pathogenesis of Crohn's disease: Are they relevant for therapeutic options? Swiss Med Wkly. 2009;139:527-534.
11. te Velde AA, Verstege MI, Hommes DW. Critical appraisal of the current practice in murine TNBS-induced colitis. Inflamm Bowel Dis. 2006;12:995-999.
12. Hoult JR. Pharmacological and biochemical actions of sulphasalazine. Drugs. 1986;32:18-26. (Pubitemid 16009025)
13. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B. J Clin Invest. 1998;101:1163-1174. (Pubitemid 28125296)
14. Daniel C, Sartory N, Zahn N, et al. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4 + CD25 + regulatory T cells. J Immunol. 2007;178:2458-2468. (Pubitemid 46233446)
15. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995;182:1281-1290.
16. Sartor RB. The influence of normal microbial flora on the development of chronic mucosal inflammation. Res Immunol. 1997;148:567-576. (Pubitemid 28179021)
17. Macfarlane GT, Blackett KL, Nakayama T, et al. The gut microbiota in inflammatory bowel disease. Curr Pharm Des. 2009;15:1528-1536.